ArticlePublic health action2026
Feasibility of tuberculosis drug-induced liver injury screening under programme settings in Southern India.
Article in Public health action, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mentorship for research on TB in India: a course on Public Health Implementation Strengthening and Operational Research (MPHISOR).Public health action · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-TB drug-induced liver injury (AT-DILI) is an important treatment-related adverse event. The National TB Elimination Programme (NTEP) recommends baseline liver function testing (LFT), but systematic follow-up monitoring remains fragmented.
objectiveTo assess the operational feasibility of implementing a screening cascade among persons with TB (PwTB) at high risk for AT-DILI within routine NTEP services.
methodsCo-designed implementation research was conducted in three districts of Tamil Nadu between July and December 2025 among adults with drug-sensitive tuberculosis (TB). Persons at high risk were identified using predefined criteria. Feasibility was assessed in implementation terms, focusing on coverage of risk assessment, adherence to the screening cascade, and timeliness of follow-up testing and clinical action.
resultsOf 2,258 PwTB, 52.3% (n = 1,158) were at risk for AT-DILI. Among them, 71.2% (n = 840) underwent baseline LFT testing and 53.9% (n = 637) completed follow-up LFT within 30 days. Eighteen PwTB developed AT-DILI (1.5% incidence under programme conditions) reflecting burden with incomplete follow-up rather than true population burden.
conclusionImplementation of an AT-DILI screening cascade within routine NTEP services was partially feasible. Risk identification was operationally achievable, but baseline and follow-up testing remained suboptimal. Gaps in follow-up monitoring and documentation highlight the need for strengthened supervision, accountability, and system support before wider scale-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.